logo-loader
viewOrgenesis

Orgenesis teams up with Johns Hopkins University to develop gene therapies with its POCare platform

Its point-of-care platform advances the development of gene-based medicine through collaborations and in-licensing

Johns Hopkins University building
Orgenesis CEO Vered Caplan is confident in the pedigree and resources of the Baltimore research university

Orgenesis Inc (NASDAQ:ORGS) announced a collaboration with Johns Hopkins University to utilize its point-of-care platform to develop and supply gene therapies and technologies. 

The company’s POCare cell therapy platform is designed to advance the development of Advanced Therapy Medicinal Products — medicines based on genes, tissues or cells — through collaborations and in-licensing with other companies. 

CEO Vered Caplan is confident in the pedigree and resources of the Baltimore research university. 

READ: Orgenesis stock flies as it completes sale of Masthercell subsidiary to get $127M pay day

“JHU has unparalleled capabilities in the cell and gene therapy sector,” Caplan said in a statement. Our POCare platform is designed to provide unique cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed systems and other advanced cell processing technologies at the point of care.

“We look forward to utilizing our POCare platform to support JHU’s growing development and processing needs in order to advance and accelerate cell and gene based clinical therapeutic research. We believe this collaboration with JHU, a clear leader in the field of cell and gene therapy, further validates the significant value proposition of our POCare platform.”

Johns Hopkins is the third major institution to sign an agreement with Orgenesis, Caplan said. Last month, the company reached a deal with the University of California, Davis.

With its introduction of Orgenesis’s POCare platform, hospitals are able to implement the company's proprietary automated, closed systems and know-how to collect, process and supply cells for various treatments such as the manufacturing of CAR-T cell therapies.

The Germantown, Maryland-based company provides centralized contract development and manufacturing organization (CDMO) services, as well as localized point-of-care development and processing centers through its subsidiary Orgenesis Maryland Inc.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Orgenesis

Price: 3.14 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $57.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read